Danish Construction Stock News

GN Store Nord stock came into this earnings print under pressure, down about 12% over the past week and weaker over the past quarter as well. The headline from Q2 is not a growth story. The group booked a loss from continuing operations and reported basic earnings per share of DKK 1.56 in the red, even though revenue from continuing operations reached DKK 2,171m. The key issue for investors is the balance sheet and valuation strain. Net interest bearing debt of DKK 9.6b remains heavy, while...

Vestas Wind Systems (CPSE:VWS) drew investor attention after reporting second quarter 2026 earnings, with higher sales and net income than a year earlier, while also raising EBIT margin guidance for the full year. See our latest analysis for Vestas Wind Systems. The earnings release and raised margin outlook appear to be contributing to building momentum in Vestas Wind Systems, with a 30 day share price return of 15.19% and a 1 year total shareholder return of 56.28% from a lower base, even...

Coloplast stock closed at DKK441.8 on Wednesday, only modestly higher over the past week and month, even after investors digested a quarter that quietly reset the earnings narrative. The headline is a sharp profit rebound. Q3 basic earnings per share landed at 6.49 DKK with net income of DKK1,462m and total revenue of DKK7,355m. The market still carries the scar of the recent one off loss that dragged the trailing net margin down to 7.5%. Today’s calm price action suggests investors are...

Royal Unibrew stock has slipped over the past week and month, yet today’s earnings story is less gloomy than the recent price action suggests. The brewer delivered Q2 revenue of DKK 4,426m and basic earnings per share of DKK 11.1, with trailing earnings putting the stock on a P/E of 13x, below both peers and the wider European beverage group. The real tension for investors is between that value label and a business still nudged by modest growth and higher debt, which sets the stage for a...

Why Genmab’s latest earnings and guidance update matters for investors Genmab (CPSE:GMAB) reported second quarter 2026 results with higher sales but lower net income compared with a year earlier. The company also raised full year revenue guidance, giving investors an updated view of expected performance. See our latest analysis for Genmab. Genmab’s latest earnings release and raised revenue guidance have coincided with strong recent momentum, with a 30 day share price return of 12.57% and a...

As the European markets navigate a landscape marked by resilient economic data and geopolitical uncertainties, investors are increasingly looking towards diverse opportunities. Penny stocks, though an older term, continue to attract attention due to their potential for growth at lower price points. These smaller or newer companies can offer unique investment opportunities when backed by strong financials and solid fundamentals.

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of second-quarter numbers that could potentially...

Jeudan earnings event puts focus on revenue and profit trends Jeudan (CPSE:JDAN) reported second quarter 2026 results that showed higher sales but lower net income and earnings per share compared with the same period in 2025. Investors now have fresh numbers to reassess the stock. See our latest analysis for Jeudan. Jeudan's latest earnings update comes as the stock trades at DKK204.0, with a 1-day share price return of 0.99% and a year-to-date share price gain of 3.55%. Over the same period,...

As the European market navigates a landscape marked by resilient economic data and geopolitical uncertainties, the STOXX Europe 600 Index recently closed slightly lower, reflecting investor caution amid these mixed signals. Despite these challenges, opportunities may exist for investors seeking undervalued stocks that could benefit from current sector shifts and regional economic resilience. In this context, identifying stocks trading below their estimated value can be particularly appealing...

A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) just released its quarterly report and things are looking bullish. A.P. Møller...

Shareholders of DFDS A/S ( CPH:DFDS ) will be pleased this week, given that the stock price is up 19% to kr.155...

It's been a good week for Solar A/S ( CPH:SOLAR B ) shareholders, because the company has just released its latest...

Aktieselskabet Schouw went into this report with the stock at DKK680 after a solid run over the past month, and the market is now weighing whether that optimism matches the earnings reality. The headline is clear: Q2 2026 delivered a sharp jump in profitability, with basic earnings per share at DKK14.18 and net income at DKK321m, both well ahead of Q1. In addition, management lifted full year revenue and EBITDA guidance for 2026, which puts the focus firmly on whether this improvement looks...

Global bond yields have pushed higher as inflation expectations adjust, which has pressured long term rates and made dependable cash flows more valuable in pricing models. When markets focus on macro swings, stocks with solid projected cash generation that also trade below fair value can get overlooked. This article highlights 3 stocks from the Undervalued Stocks Based On Cash Flows screener that stand out on this theme. The 3 stocks highlighted below are just a small sample, since the full...

FLSmidth (CPSE:FLS) stock is back in focus after the company named Petri Virrankoski as President of its Service Business Line, with a planned 2027 start. The appointment underscores attention on the service segment. See our latest analysis for FLSmidth. The leadership news comes at a time when FLSmidth’s recent momentum has been positive. The 1 month share price return is 6.38% and the 1 year total shareholder return is 27.11%. In addition, the 5 year total shareholder return of 155.07%...

Ørsted stock went into this earnings release under pressure, with the share price down about 14% over the past three months and trading at DKK139.2 at Thursday’s close. The market has been wrestling with an unprofitable trailing year and questions about how the balance sheet will fund a heavy offshore build out. The headline from this quarter is not the income statement. It is the funding capacity. Net debt of DKK22b, a liquidity reserve above DKK115b and a funds from operations to adjusted...

A.P. Møller - Mærsk stock went into this earnings print with a strong run, up about 30% over the past three months and firmly in recovery-story territory. The latest numbers now test that optimism. The headline is profit pressure. Trailing net profit margin sits at 3% compared with 12.6% a year earlier, even as revenue over the last twelve months totals about US$53.6b. The market is weighing a richer P/E of 26.3x against this thinner profitability. This makes this quarter less about volume...

Zealand Pharma stock came into today on a strong run, up 22% over the past month and 10% over three months, with investors leaning into its low 3.7x P/E and fresh profitability over the last year. The earnings release keeps that tension front and center. H1 revenue landed at DKK 4.5b, powered by a DKK 3.7b Phase III milestone and a DKK 798m payment from Roche, and management highlighted DKK 14.5b of cash on hand. The question now is how long that earnings and cash firepower can support the...

European equities have recently experienced a boost, with the pan-European STOXX Europe 600 Index climbing 1.70% due to improved risk appetite and resilient earnings, despite ongoing geopolitical uncertainties. In this environment of cautious optimism, identifying undervalued stocks can be a strategic move for investors seeking opportunities that are priced below their estimated worth.

Russia’s war in Ukraine has turned European energy into a pressure point again, with supply routes, winter demand and sanctions all back in focus. That mix of risk and rearranged trade flows can quickly change how investors look at European Energy Sector stocks. This article walks through three stocks from our screener that appear positively exposed to the latest news, and explains what makes each one worth a closer look now. The three European energy stocks highlighted below are just a...

It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...

In July 2026, Genmab A/S and AbbVie clarified that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma did not achieve a statistically significant improvement in overall survival, the sole primary endpoint in the United States. This clarification highlights the complexity of region-specific trial endpoints and leaves investors waiting for detailed peer-reviewed data to understand epcoritamab’s broader clinical profile. We’ll now examine how...

In recent weeks, global markets have been navigating a complex landscape marked by rising oil prices, geopolitical tensions in the Middle East, and fluctuating investor sentiment around AI investments. Amid these challenges, major indices like the Nasdaq Composite and S&P 500 have faced declines, while European markets showed resilience with modest gains. In such an environment, identifying undervalued stocks can be crucial for investors seeking opportunities that may offer potential...

Danske Bank (CPSE:DANSKE) is back in focus after raising its 2026 net profit guidance to DKK 23b to DKK 25b and targeting around 14% return on equity, alongside fresh second quarter earnings. See our latest analysis for Danske Bank. At a share price of DKK362.4, Danske Bank has seen its 1 month share price return of 5.13% build on a 3 month gain of 10.02%. The 1 year total shareholder return of 52.45% and 5 year total shareholder return of 355.31% point to strong longer term momentum around...